Skip to main content
Download PDF

Role of mast cells in the pathogenesis of severe lung damage in COVID-19 patients

Respiratory Research volume 23, Article number: 371 (2022) Cite this article

Abstract

Background

There is still insufficient knowledge with regard to the potential involvement of mast cells (MCs) and their mediators in the pathology of coronavirus disease-2019 (COVID-19). Therefore, our study aimed to investigate the role of MCs, their activation and protease profiles in the pathogenesis of early and late lung damage in COVID-19 patients.

Methods

Formalin-fixed and paraffin embedded lung specimens from 30 patients who died from COVID-19 and 9 controls were used for histological detection of MCs and their proteases (tryptase, chymase) followed by morphometric quantification.

Results

Our results demonstrated increased numbers of MCs at early stage and further augmentation of MCs number during the late stage of alveolar damage in COVID-19 patients, as compared to the control group. Importantly, the percentage of degranulated (activated) MCs was higher during both stages of alveolar lesions in comparison to the controls. While there was no prominent alteration in the profile of tryptase-positive MCs, our data revealed a significant elevation in the number of chymase-positive MCs in the lungs of COVID-19 patients, compared to the controls.

Conclusions

MCs are characterized by dysregulated accumulation and increased activation in the lungs of patients suffering from COVID-19. However, future profound studies are needed for precise analysis of the role of these immune cells in the context of novel coronavirus disease.

Clinical message

Our data shed the further light on the clinical issue of dysregulated lung inflammation, with particular focus on mast cells, in the context of COVID-19. This can provide an avenue for future development of targeted therapy against hyper-activated mast cells in order to treat COVID-19 patients.

Introduction

Coronavirus disease 2019 (COVID-19) is a new infectious disease whose clinical manifestations range from asymptomatic to severe acute respiratory syndrome with widespread lung tissue damage that can cause mortality from this disease. Severe COVID-19 results in diffuse alveolar damage accompanied by the alveolar-hemorrhagic syndrome and widespread thrombosis of the microvasculature leading to hypoxia and respiratory failure [1, 2]. Lung pathology in COVID-19 is thought to be immune-mediated and exacerbated by the infiltration of monocytes, neutrophils, and subpopulations of T lymphocytes [3]. A cytokine storm causing much greater mortality than any direct viral cytotoxicity has been identified in about 15–20% of patients suffering from COVID-19 with severe lung damage [4]. COVID-19-associated cytokine storm is characterized by rapid proliferation and hyperactivation of the T-cell link, macrophages, and natural killer cells, as well as increased production of inflammatory cytokines and chemokines released by immune or non-immune cells [2, 5,6,7,8]. One of the sources of such cytokines and chemokines are mast cells (MCs), which are found everywhere in the body, especially in the organs of the respiratory system, and are crucial in the development of a number of pathological conditions [7, 9, 10].

MCs are a ubiquitous pool of cells of myeloid lineage strategically localized in the functionally significant areas of the body, including the skin, respiratory system, gastrointestinal mucosa, for optimal functional interaction with immunocompetent and stromal cells, as well as extracellular structures of a specific tissue microenvironment. MCs are represented by a highly heterogeneous cell population with subtype-dependent differences in morphology, histochemical properties, protease expression, and function. MCs have broad multifunctional properties associated with the release of many preformed mediators, phagocytosis, antigen processing, cytokine production, etc. [11, 12]. They can also recruit immune cells into the focus of inflammation, secreting chemokines and other mediators that can locally increase vascular permeability [12]. Histamine released by MCs in combination with interleukin (IL)-1 can cause increased lung inflammation resulting from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection [13]. Certain mediators derived from MCs, proteases, such as β-tryptases, chymases, and carboxypeptidase A (CPA)-3 are considered specific for MCs and indicate the state of their activation [12, 14]. The functionality of serine proteases, especially tryptases and chymases, has led to an interest in studying the regulatory effects on the course of coronavirus infection. For example, it is known that chymase engages in the active hydrolysis of angiotensin I to angiotensin II, thereby being a potential participant in the development of heart failure and pulmonary hypertension [15].

Importantly, scientists in many countries are actively studying pathomorphology of the lung lesions in COVID-19, but only a few studies are devoted to the role of MCs in the pathogenesis of the disease. Therefore, our study objective was to assess the protease profile of MCs and the role of their activation in the pathogenesis of early and late lung damage in the context of the novel coronavirus infection.

Methods

This morphological study was carried out based on the materials of 39 autopsies of the lungs in the “Voronezh Regional Pathological Bureau” and approved by the local ethics committee of the Burdenko Voronezh State Medical University (protocol №8, September 17, 2021). We studied autopsy lung specimens from 30 patients who died from COVID-19 and from 9 patients who died by accident or who died from other diseases in which the lungs were not pathologically affected (control group). This retrospective study included material only from those patients whose bodies were unclaimed by relatives after death (unclaimed corpses) and were subjected to municipal burial.

After sampling during autopsy and fixation in 10% neutral buffered formalin, paraffin embedding was carried out according to the standard sample preparation procedure [16]. From paraffin blocks, prepared sections with a thickness of 5 μm were used for staining with hematoxylin and eosin, Giemsa's dye, and picro Mallory. For immunohistochemical analysis, ultrathin sections, 2 µm thick, were prepared. Immunohistochemical staining was performed according to the standard protocol [16], detecting MC proteases—tryptase and chymase and evaluating the proliferation of type II alveolocytes by expression of PCNA. The identification of proteases was carried out using the primary mouse antibodies Anti-Mast Cell Tryptase antibody (clone AA1, #ab2378, dilution 1:4000) and Anti-Mast Cell Chymase antibody (#ab233103, dilution 1:1000), nuclear protein PCNA was detected using immunolabeling with primary rabbit monoclonal antibodies Anti-PCNA antibody (Epitomics #AC-0087RUO, clone EP91, dilution 1:1000, USA). Goat anti-rabbit and anti-mouse antibodies # AS-R1-HRP were used as secondary antibodies, which, in turn, visualized with ImmPACTTM DAB Peroxidase Substrat Kit (# SK-4105) according to the protocol specified in the instructions. The nuclei were contrasted with Mayer’s hematoxylin, after which the slices were placed in the mounting medium. The state of MC activation was assessed by the quantitative representation of tryptase and chymase-positive mast cells [9,10,11].

The stained micro-preparations were studied on a ZEISS Axio Imager.A2 microscope with a photo documentation system equipped with a Camera Axiocam 506 color digital camera. The images were processed using ZEN 2.3 software (Carl Zeiss, Germany). The total number of MCs was counted on the × 40 lens with the analysis of at least 50 fields of view. Planimetric analysis of micro-preparations included counting of MCs metachromatically stained with Giemsa dye, followed by functional distribution according to the degree of degranulation, and quantitative analysis of the protease profile (tryptase, chymase) per mm2.

The results were statistically processed using STATGRAPHICS Centurion XV software package. The normality of data distribution was assessed using normalized kurtosis and skewness coefficients. Quantitative data under normal distribution were presented as mean ± SEM, where SEM was standard error of the mean. If the sample did not meet the criteria for normal distribution, the data were presented as a median; the upper and lower quartiles were indicated in brackets. In the case of normal distribution, the comparison of variables was carried out using a one-way analysis of variance (ANOVA). If variables did not meet the criteria of normal distribution, the comparison was carried out using the Mann–Whitney U-test. p-value < 0.05 was considered significant.

Results

Between September 21 and November 30, 2021, thirty patients with confirmed SARS-CoV-2 infection were included in the study. Twenty-one (70%) of patients were men, nine (30%) were women, and all patients were Caucasian. The mean age at death was 66.1 ± 15.7 years. Diabetes mellitus (70%), chronic kidney disease (50%) and coronary heart disease (37%) were the most common comorbidities. The majority of patients were obese (80%), with a mean body-mass index (BMI) 31.1 ± 4.9 kg/m2. All patients (100%) had acute respiratory distress syndrome (ARDS), were intubated and received invasive mechanical ventilation. The mean time of respiratory support was 10.4 ± 1.9 days. All patients (100%) were treated with systemic steroids. The mean duration of hospitalization was 12.5 ± 2.7 days, and the mean interval from symptom onset to death was 22.7 ± 3.8 days. Baseline demographic and clinical characteristics are shown in Table 1.

Table 1 COVID-19 patients’ baseline demographic and clinical characteristics
Full size table

Patients in control group (n = 9) had similar age (62.2 ± 6.8 years) and similar spectrum of comorbidities (obesity 67%, diabetes 56%, coronary heart disease 33%).

The early stage (Fig. 1) of diffuse alveolar damage (n = 15) was characterized by the following macroscopic changes: lung was light pasty to the touch, with areas of rubbery density on the rear surfaces, and reddish-violet on the surface. On the incisions, the lung tissue was grey-red; and a large amount of dark red foamy liquid was released from the surface of the incisions when pressed. Microscopic changes in this stage were represented by distelectasis, plethora of inter-alveolar septa, and accumulations of serous-purulent exudate in the lumens of the alveoli sporadically with an admixture of pinkish protein fluid with desquamated alveolocytes. Further, hyaline membranes were located parietally over a greater extent; the respiratory epithelium of the bronchial mucosa was desquamated and there were mixed blood clots in the lumens of some small branches of the pulmonary artery. The late stage (Fig. 2) of diffuse alveolar damage (n = 15) was macroscopically characterized by a dense-elastic consistency of the affected lungs, with a variegated surface due to alternation due to grey-pink, reddish-purple, and dark red areas. On incisions the lung tissue was airless with a complete loss of porous alveolar structures, greyish-reddish in color with dark red areas, a large amount of light red fluid is released from the surface of the incisions when pressed. Microscopically, in the stage of the late diffuse alveolar damage, there was pronounced vascular congestion of the inter-alveolar septa; there were erythrocytes with an admixture of macrophages in the lumens of the alveoli and proliferation of type II alveolocytes. Some alveoli contained filaments of fibrin, partly with the proliferation of fibroblasts, the beginning of the granulation tissue formation, and foci of squamous metaplasia of the alveolar epithelium. Multiple hyaline membranes lined the contours of the alveoli. Diffuse interstitial lymphoplasmacytic infiltration with an admixture of a small number of neutrophils was observed.

Fig. 1
figure 1

Microscopic changes in the lung tissues of patients who have died from COVID-19 (staining with hematoxylin and eosin). A Diffuse alveolar damage in the acute stage; the walls of the alveoli are filled with dense eosinophilic masses of fibrin, hyaline membranes (arrows); in the lumen of the alveoli, you can observe individual filaments of fibrin. B Diffuse alveolar damage in the acute stage, the lumen of the alveoli is filled with fibrin filaments, single erythrocytes, cells of the respiratory epithelium, and polymorphonuclear leukocytes. C Diffuse alveolar damage in the acute stage, round and oval cells almost completely filling the lumen of the alveoli. D Proliferation of type II alveolocytes leads to the formation of bizarre epithelial structures. Scale bars A, C, D—100 μm, B—50 μm

Full size image
Fig. 2
figure 2

Late injury pattern in the lung tissue. Pronounced phenomena of the organization. Fixation: 10% neutral formalin. Technique: staining with hematoxylin and eosin (A, B) and picro Mallory (C) and PCNA was detected using immunolabeling with primary rabbit monoclonal antibodies Anti-PCNA antibody (Epitomics #AC-0087RUO, clone EP91, dilution 1:1000, USA), (D). A A late stage diffuse alveolar damage; the walls of the alveoli are thickened, hemorrhages and desquamation of the alveolar epithelium are observed, the focus of inflammatory infiltration is represented by lymphocytes. B A late stage diffuse alveolar damage; pronounced fibrosis of the alveolar septa, desquamation of the alveolar epithelium. C A late stage diffuse alveolar damage; special staining reveals the connective tissue fibers (blue color), focal hemorrhages, desquamation of the alveolar epithelium. D Expression of PCNA in type II alveolocytes (brown staining). Scale bars A–C—100 μm, D—50 μm

Full size image

Analysis of histological preparations just on plain staining with hematoxylin and eosin, revealed an extensive representation of inflammatory cells in the affected tissues. These were diffuse and focal accumulations of lymphocytes, plasma cells, neutrophils, and eosinophils. Special methods made it possible to identify mast cells in the tissues of the affected lungs. They were also widely represented in all studied cases.

Control group samples presented numerous MCs. In most cases, the cells were localized in the perivascular spaces between the alveolar sacs and terminal bronchioles and in the alveolar septa, close to the alveolar capillaries (the result presented in Table 2). The percentage of MCs with signs of degranulation was 43.3% while 38.8% did not contain signs of degranulation. In control samples of lung tissue, mast cells formed autonomous, separately lying granules in 17.9%.

Table 2 The distribution of mast cells in the affected lung tissues of patients with early and late stages of alveolar damage (staining with Giemsa dye)
Full size table

Evaluation of the distribution of MCs and their proteases in COVID-19 patients with different stages of alveolar lesions revealed some interesting features (Tables 2 and 3, Fig. 3). There was an increase in the number of MCs at early stage of alveolar damage (p = 0.042) and further augmentation of MCs number during the late stage of alveolar damage (p = 0.034), as compared to the control group. Furthermore, the percentage of degranulated MCs was higher during the early and late stages of alveolar lesions in comparison to the control group. The data obtained indicated a significant representation of MCs in the affected parts of the lungs. A high percentage of MCs with signs of degranulation indicated their activation and participation in the inflammatory process. Finally, we have also analyzed the MCs protease (tryptase and chymase) profiles in our samples. We found that there was no prominent alteration in tryptase-positive MCs between the control and COVID-19 groups. However, there was a significant augmentation in the number of chymase-positive MCs in the lungs of COVID-19 patients, compared to the controls. It is noteworthy that in this study, we found an interesting fact of the formation of clusters of degranulating MCs expressing tryptase and chymase in areas of the lung with hemorrhagic phenomena (Fig. 3), which may be related to the role of histamine as a mediator that aggravates the course of the disease.

Table 3 Protease profile (tryptase, chymase) and secretory activity of mast cells in the affected lung tissues
Full size table
Fig. 3
figure 3

Mast cells in the lung tissues of COVID-19 patients. A–C Immunohistochemical staining with mouse monoclonal antibodies to tryptase (Abcam, # ab2378, dilution 1:4000) in accordance with standard protocol; D–F Immunohistochemical staining with mouse monoclonal antibodies to chymase (Abcam, #ab233103, dilution 1:1000). The peroxidase label on antibodies was visualized using DAB as a substrate (Vector Laboratories, Burlingame, CA, USA). The slices contrasted with Mayer’s hematoxylin. A, B Early diffuse alveolar injury, mast cell tryptase expression; mast cells are unevenly distributed in the alveolar septa. C Early diffuse alveolar damage, active degranulation of MCs, arrow indicates mast cell at the end of degranulation. D, E Uneven distribution of MCs with chymase expression. F Pronounced degranulation of mast cell chymase (arrows) with alveolar damage in the late stage. Scale bars A—100 μm, others—50 μm

Full size image

Discussion

Overall, our study has demonstrated altered distribution of MCs in the affected lung tissues in COVID-19 patients with different stages of alveolar damage. In the studied preparations, particularly the late stage of alveolar damage was accompanied by an increase in both the total number of MCs per mm2 and other parameters, in comparison to the control lungs. Quantitative characteristics of the content of MCs and indicators of their activity (degranulation) corresponded to histological changes in the lung tissue in the early and late stages of alveolar damage. Therefore, at the early stage, patterns of alteration and exudation predominated, apparently taking place with the direct participation of MCs. In the later stages, patterns of proliferative inflammation began to join and the regulatory role of MCs increased, the fact supported by quantitative changes. It was also noted the formation of clusters of degranulating MCs expressing tryptase and chymase in areas of the lung with hemorrhagic phenomena (Fig. 3).

Histological examination of the lungs of patients who died from SARS-CoV-2 infection revealed extensive infiltration of immune cells, including MCs, in the interstitium and alveoli [7, 13, 17, 18]. Such a significant representation of MCs in the affected lung tissue certainly indicated their involvement in the pathological process. MCs activation by increased tryptase and chymase secretion in both mild and severe COVID-19-associated lung tissue lesions only confirms their active role in the pathogenesis of inflammation.

There are many mechanisms of MCs activation in a pathological process, and in the case of lung damage in COVID-19 patients, this question remains open. MCs are activated by allergens, but they can also be caused by molecular pathogens through the activation of Toll-like receptors (TLR) [7, 19]. Viruses can activate MCs through TLR [14] with a subsequent increase in expression of inflammatory mediators. Moreover, MCs can detect damage-associated molecular structures (DAMPs) from various types of viruses, and in the same way detect SARS-CoV-2 infection and respond to it.

Innate immune cells can be activated by DAMPs and pathogen-associated molecular structures (PAMP) in COVID-19 patients [19,20,21,22,23,24]. Some literature sources suggested that MCs may express angiotensin-converting enzyme 2 (ACE2), which is known as the main receptor for SARS-CoV-2, and serine proteases, including the cell surface transmembrane protease serine 2, which are required to prime the coronavirus spike protein [7, 18, 19, 24, 25]. Conversely, the recent findings do not indicate the detectable levels of ACE-2 expression in the bone marrow MCs [26]. Therefore, this scientific question remains to be ultimately resolved in the future research. Moreover, MCs express a number of serine proteases that may be linked to the pathology of infection with SARS-CoV-2 [3, 9, 10]. Human MCs can be synergistically stimulated by peptide substance P and IL-33 to release a significant amount of vascular endothelial growth factors, IL-1β, or tumor necrosis factor without secretion of histamine or tryptase [23, 27]. SARS-CoV-2 induces the production of IL-1 by relevant cells, including MCs, causing induction of gene expression and activation of other pro-inflammatory cytokines. Since IL-1 is toxic, its production from MCs and macrophages activated by SARS-CoV-2 can also trigger gastrointestinal and brain disorders [13, 21]. Histamine is stored endogenously within the secretory granules of MCs and is involved in the increased expression of chemokine IL-8 and cytokine IL-6, thus favoring the hyper-inflammation in the lung. Therefore, in the context of COVID-19 cytokine storm and severe disease, histamine produced by MCs may induce the appearance of the microvascular leakage, proteases, and IL-6 that can degrade matrix. This may subsequently lead to the intra-alveolar formation of the hyaline membrane and perpetuation of inflammation, with release of angiogenic factors and pro-coagulative factors that may trigger immune thrombosis [28]. In the lung samples, we observed chymase-positive MCs with signs of active degranulation in the areas of damaged tissues, characterized by edema, hemorrhages and necrosis. It is known that chymase activates transforming growth factor-β (TGF-β) and matrix metalloproteinase (MMP) 9, converting their precursors into active forms involved in inflammation and fibrosis of tissues, which leads to structural damage and remodeling of organs, as well as to increased coagulation, which may be important in the pathogenesis of COVID-19 [7, 11, 21,22,23, 25, 29, 30].

The indication that hyper-activated MCs and the developing cytokine storm contribute to the severe course of COVID-19 is described [12, 25, 31, 32]; this fact suggests new possibilities (approaches) in the pharmacotherapy of both the acute process and post-COVID-19 period. However, some studies provided a contrasting data with regard to the topic of the involvement of MCs in the pathology of COVID-19. Schaller et al. found differences in the MCs numbers between early and late stages of the lung damage, suggesting that MCs may play a role in the later stages [33]. In addition, Giannetti and colleagues concluded that MCs activation is not important phenomenon in the context of COVID-19 [26].

Conclusions

The study of the role of MCs in COVID-19 associated lung damage can shed light on the specifics of the pathogenesis of this disease, the severity of its manifestation, and the mechanisms of development of fatal cases. In addition, the involvement of MCs in the pathological process may give an opportunity to develop targeted therapy for COVID-19 patients by pharmacological interference with MCs activation (degranulation) and inhibition of their mediators. Finally, the determination of proteins specific for MCs in biological fluids may allow us to predict the clinical course in a particular patient. However, all these future possibilities require further and profound study of this important scientific and clinical issue.

Availability of data and materials

Data are available from the corresponding author upon the reasonable request.

References

  1. Calabrese F, Pezzuto F, Fortarezza F, Hofman P, Kern I, Panizo A, von der Thusen J, Timofeev S, Gorkiewicz G, Lunardi F. Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists. Virchows Arch. 2020;477:359–72.

    Article  CAS  Google Scholar 

  2. Martin Gimenez VM, Inserra F, Tajer CD, Mariani J, Ferder L, Reiter RJ, Manucha W. Lungs as target of COVID-19 infection: protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment. Life Sci. 2020;254: 117808.

    Article  CAS  Google Scholar 

  3. Song JW, Zhang C, Fan X, Meng FP, Xu Z, Xia P, Cao WJ, Yang T, Dai XP, Wang SY, Xu RN, Jiang TJ, Li WG, Zhang DW, Zhao P, Shi M, Agrati C, Ippolito G, Maeurer M, Zumla A, Wang FS, Zhang JY. Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nat Commun. 2020;11:3410.

    Article  CAS  Google Scholar 

  4. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–3.

    Article  CAS  Google Scholar 

  5. Mangalmurti N, Hunter CA. Cytokine storms: understanding COVID-19. Immunity. 2020;53:19–25.

    Article  CAS  Google Scholar 

  6. Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol. 2020;92:548–51.

    Article  CAS  Google Scholar 

  7. Theoharides TC. Potential association of mast cells with coronavirus disease 2019. Ann Allergy Asthma Immunol. 2021;126:217–8.

    Article  CAS  Google Scholar 

  8. El-Missiry MA, El-Missiry ZMA, Othman AI. Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of Covid-19. Eur J Pharmacol. 2020;882: 173329.

    Article  CAS  Google Scholar 

  9. Atiakshin D, Buchwalow I, Samoilova V, Tiemann M. Tryptase as a polyfunctional component of mast cells. Histochem Cell Biol. 2018;149:461–77.

    Article  CAS  Google Scholar 

  10. Atiakshin D, Buchwalow I, Tiemann M. Mast cell chymase: morphofunctional characteristics. Histochem Cell Biol. 2019;152:253–69.

    Article  CAS  Google Scholar 

  11. Shishkina VV, Klochkova SV, Alexeeva NT, Soboleva MYu, Esaulenko DI, Antakova LN, Gerasimova OA, Samodurova NYu, Samoilenko TV. Tryptase profile of the rat skin mast cell population during the wound healing. J Anatomy Histopathol. 2020;9:84–9.

    Article  Google Scholar 

  12. Tan J, Anderson DE, Rathore APS, O’Neill A, Mantri CK, Saron WAA, Lee C, Cui CW, Kang AEZ, Foo R, Kalimuddin S, Low JG, Ho L, Tambyah P, Burke TW, Woods CW, Chan KR, Karhausen J, John ALS. Signatures of mast cell activation are associated with severe COVID-19. medRxiv. 2021;586:509.

    Google Scholar 

  13. Conti P, Caraffa A, Tete G, Gallenga CE, Ross R, Kritas SK, Frydas I, Younes A, Di Emidio P, Ronconi G. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19. J Biol Regul Homeost Agents. 2020;34:1629–32.

    CAS  Google Scholar 

  14. Gebremeskel S, Schanin J, Coyle KM, Butuci M, Luu T, Brock EC, Xu A, Wong A, Leung J, Korver W, Morin RD, Schleimer RP, Bochner BS, Youngblood BA. Mast cell and eosinophil activation are associated with COVID-19 and TLR-mediated viral inflammation: implications for an anti-siglec-8 antibody. Front Immunol. 2021;12: 650331.

    Article  CAS  Google Scholar 

  15. Kosanovic D, Luitel H, Dahal BK, Cornitescu T, Janssen W, Danser AH, Garrelds IM, De Mey JG, Fazzi G, Schiffers P, Iglarz M, Fischli W, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, Reiss I, Schermuly RT. Chymase: a multifunctional player in pulmonary hypertension associated with lung fibrosis. Eur Respir J. 2015;46:1084–94.

    Article  CAS  Google Scholar 

  16. Buchwalow IBB, W. Immunohistochemistry: Basics and Methods. 1st ed Springer; Berlin/Heidelberg, Germany. 2010.

  17. Gigante A, Aquili A, Farinelli L, Caraffa A, Ronconi G, Enrica Gallenga C, Tete G, Kritas SK, Conti P. Sodium chromo-glycate and palmitoylethanolamide: a possible strategy to treat mast cell-induced lung inflammation in COVID-19. Med Hypotheses. 2020;143: 109856.

    Article  CAS  Google Scholar 

  18. Hadzic S, Wu CY, Avdeev S, Weissmann N, Schermuly RT, Kosanovic D. Lung epithelium damage in COPD—an unstoppable pathological event? Cell Signal. 2020;68: 109540.

    Article  CAS  Google Scholar 

  19. Lam HY, Tergaonkar V, Kumar AP, Ahn KS. Mast cells: therapeutic targets for COVID-19 and beyond. IUBMB Life. 2021;73:1278–92.

    Article  CAS  Google Scholar 

  20. Wu ML, Liu FL, Sun J, Li X, He XY, Zheng HY, Zhou YH, Yan Q, Chen L, Yu GY, Chang J, Jin X, Zhao J, Chen XW, Zheng YT, Wang JH. SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injury. Signal Transduct Target Ther. 2021;6:428.

    Article  CAS  Google Scholar 

  21. Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;100:327–32.

    Article  CAS  Google Scholar 

  22. Yang J, Pan X, Wang L, Yu G. Alveolar cells under mechanical stressed niche: critical contributors to pulmonary fibrosis. Mol Med. 2020;26:95.

    Article  Google Scholar 

  23. Zhou Y, Hou Y, Shen J, Mehra R, Kallianpur A, Culver DA, Gack MU, Farha S, Zein J, Comhair S, Fiocchi C, Stappenbeck T, Chan T, Eng C, Jung JU, Jehi L, Erzurum S, Cheng F. A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19. PLoS Biol. 2020;18: e3000970.

    Article  CAS  Google Scholar 

  24. Ribeiro Dos Santos Miggiolaro AF, da Silva Motta Junior J, Busatta Vaz de Paula C, Nagashima S, Alessandra Scaranello Malaquias M, Baena Carstens L, Moreno-Amaral AN, Pellegrino Baena C, de Noronha L. Covid-19 cytokine storm in pulmonary tissue: Anatomopathological and immunohistochemical findings. Respir Med Case Rep. 2020;31:101292.

    Google Scholar 

  25. Theoharides TC. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin. BioFactors. 2020;46:306–8.

    Article  CAS  Google Scholar 

  26. Giannetti MP, Weller E, Alvarez-Twose I, Torrado I, Bonadonna P, Zanotti R, Dwyer DF, Foer D, Akin C, Hartmann K, Rama TA, Sperr WR, Valent P, Teodosio C, Orfao A, Castells M. COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms. J Allergy Clin Immunol Pract. 2021;9:2083–6.

    Article  CAS  Google Scholar 

  27. Caughey GH, Raymond WW, Wolters PJ. Angiotensin II generation by mast cell alpha- and beta-chymases. Biochim Biophys Acta. 2000;1480:245–57.

    Article  CAS  Google Scholar 

  28. Murdaca G, Di Gioacchino M, Greco M, Borro M, Paladin F, Petrarca C, Gangemi S. Basophils and mast cells in COVID-19 pathogenesis. Cells. 2021;10:2754.

    Article  CAS  Google Scholar 

  29. Atiakshin D, Samoilova V, Buchwalow I, Tiemann M. Expression of CD38 in mast cells: cytological and histotopographic features. Cells. 2021;10:2511.

    Article  CAS  Google Scholar 

  30. Abassi Z, Skorecki K, Hamo-Giladi DB, Kruzel-Davila E, Heyman SN. Kinins and chymase: the forgotten components of the renin-angiotensin system and their implications in COVID-19 disease. Am J Physiol Lung Cell Mol Physiol. 2021;320:L422–9.

    Article  CAS  Google Scholar 

  31. Gustine JN, Jones D. Immunopathology of hyperinflammation in COVID-19. Am J Pathol. 2021;191:4–17.

    Article  CAS  Google Scholar 

  32. Liu Z, Xiao X, Wei X, Li J, Yang J, Tan H, Zhu J, Zhang Q, Wu J, Liu L. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J Med Virol. 2020;92:595–601.

    Article  CAS  Google Scholar 

  33. Schaller T, Markl B, Claus R, Sholl L, Hornick JL, Giannetti MP, Schweizer L, Mann M, Castells M. Mast cells in lung damage of COVID-19 autopsies: a descriptive study. Allergy. 2022;77:2237.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

The study was supported by extrabudgetary resources of N.N. Burdenko Voronezh State Medical University of the Ministry of Healthcare of the Russian Federation.

Author information

Authors and Affiliations

  1. Department of Faculty Therapy, Burdenko Voronezh State Medical University, 10 Studencheskaya Str., Voronezh, Russia, 394036

    Andrey V. Budnevsky & Evgeniy S. Ovsyannikov

  2. Department of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia, Trubetskaya Street 8, 119991, Moscow, Russia

    Sergey N. Avdeev, Djuro Kosanovic & Olga A. Suvorova

  3. Scientific Research Institute of Experimental Biology and Medicine, Burdenko Voronezh State Medical University, Moskovsky Prospect, 185, Voronezh, Russia, 394036

    Victoria V. Shishkina, Dmitry I. Esaulenko, Tatiana V. Samoylenko & Alexander N. Redkin

  4. Budgetary Health Care Institution of the Voronezh Region “Voronezh Regional Pathoanatomical Bureau”, Moskovsky Prospect, 151, Voronezh, Russia, 394036

    Andrey A. Filin

  5. Department of Pulmonology, Voronezh Regional Clinical Hospital, № 1, Moskovsky Prospect, 151, Voronezh, Russia, 394036

    Inna M. Perveeva

Authors
  1. Andrey V. Budnevsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sergey N. Avdeev
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Djuro Kosanovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Victoria V. Shishkina
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andrey A. Filin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dmitry I. Esaulenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Evgeniy S. Ovsyannikov
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tatiana V. Samoylenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Alexander N. Redkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Olga A. Suvorova
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Inna M. Perveeva
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study design: AVB; data collection: VVS, AAF, DIE, ESO, TVS, ANR, OAS, IMP; data interpretation and analysis: AVB, SNA, DK, VVS, AAF, DIE, ESO, TVS, ANR, OAS, IMP; drafting the manuscript: AVB, SNA, DK; manuscript writing: all authors were involved in the writing procedure and all authors have read and approved the final version of the manuscript.

Corresponding author

Correspondence to Sergey N. Avdeev.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the local ethics committee of the Burdenko Voronezh State Medical University (protocol №8, September 17, 2021). As this was a retrospective study, the requirement for informed consent was waived.

Consent for publication

Not applicable.

Competing interests

The authors do not have any conflict of interest with regard to this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Budnevsky, A.V., Avdeev, S.N., Kosanovic, D. et al. Role of mast cells in the pathogenesis of severe lung damage in COVID-19 patients. Respir Res 23, 371 (2022). https://doi.org/10.1186/s12931-022-02284-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12931-022-02284-3

Keywords

  • COVID-19
  • SARS-CoV-2
  • Mast cells
  • Inflammation
  • Cytokine storms

Respiratory Research

ISSN: 1465-993X

Contact us